- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03797040
Open-label Phase I Study for PEP or Treatment of HS-ARS PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) (HS-ARS)
Open-label Phase I Study to Evaluate the Safety of PLX-R18 for the Post-Exposure Prevention (PEP) or Treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)
The objective of the study is to evaluate the safety of intramuscular (IM) administration of PLX-R18 in subjects exposed to ionizing radiation and who are at risk of developing HS-ARS.
Indication:Post-Exposure Prevention (PEP) or treatment of Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS) in subjects suspected to have been exposed to ionizing radiation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This will be a Phase I, open-label safety study; each subject will receive two administrations of PLX-R18, 4 days apart. Each administration of PLX-R18 will contain 4 million cells/kg (up to a maximal dose of 400 million cells). The first administration should be preferably within 48 hours after suspected exposure and no later than 4 days after suspected exposure. The second administration will be provided 4 days after first administration.
All subjects will be hospitalized for at least 24 hours after each administration of PLX-R18,for close monitoring.In order to minimize risks, subjects will be divided in 3 sequential cohorts:
Cohort 1: 9 subjects, treated as soon as possible Cohort 2: 18 subjects, treated at least 12 hours following the first dose administered to the 9th subject Cohort 3: 33 subjects, treated at least 12 hours following the first dose administered to the 27th subject After the completion of each Cohort, stopping rules will be assessed. All subjects will receive PLX-R18 in addition to recommended care per physician discretion, based on the REMM guidelines (APPENDIX 2).
The study will be comprised of 2 periods:
Main study period - Subjects will be followed-up for 12 months and evaluated at the following time points after the first administration: Day 0 (first administration),Day 1, Day 2, Day 3, Day 4 (second administration), Day 5, Day 14 (2 weeks),Day 21 (3 weeks), Day 28 (4 weeks), Day 49 (7 weeks), Day 63 (9 weeks), Day 119(17 weeks), Day 182 (26 weeks), and Day 364 (52 weeks).Long-term survival follow-up -Week 52 to Week 260: During this period, patients will be followed-up for overall survival at: 104 weeks, 156 weeks, 208 weeks and 260 weeks.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subject was exposed or suspected to have been exposed to ionizing radiation of
≥1Gy and is at risk of developing HS-ARS, as assessed by the treating physician, based on REMM guidelines (see APPENDIX 1).
- PLX-R18 treatment can be initiated within 4 days of exposure.
- Aged ≥18 years.
- Has provided informed consent. -
Exclusion Criteria:
- Known active malignancy or history of malignancy within 3 years prior to screening except for successfully resected skin basal cell carcinoma or skin squamous cell carcinoma not located at the injection sites.
- Known active uncontrolled infection (e.g. viral, fungal, and/or bacterial)
- Known active infection with Hepatitis A, B, or C.
- Pregnancy.
- Known hypersensitivity to: Allogeneic stromal cells, dimethyl sulfoxid (DMSO), human serum albumin, or bovine products.
- In the opinion of the Investigator the subject is at high risk of developing severe allergic/hypersensitivity reactions and a resuscitation kit including epinephrine is not at hand.
In the opinion of the treating physician, the subject is unsuitable for participating in the study.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 4 million PLX-R18 cells/kg-up to a maximal dose of 400 million
|
PLX-R18: Allogeneic ex vivo expanded placental stromal cells
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Any Adverse Reaction
Time Frame: From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recovered with no sequelae
Time Frame: From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
The subject has fully recovered from the AE with no residual effects observable.
|
From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
Recovered with sequelae
Time Frame: From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
The event resolved but the subject has sequelae, which is a condition following a consequence of a disease
|
From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
Ongoing AE
Time Frame: From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
AE is still ongoing
|
From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
Overall survival
Time Frame: From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
Overall survival
|
From Week 52 to Week 260 patients will be followed-up for overall survival once a year (every 52 weeks±2 after visit 14)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PLX-R18-ARS-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ionizing Radiation Exposure
-
Total Cardiovascular SolutionsCompletedExposure to Ionizing RadiationIndia
-
National Cancer Institute (NCI)CompletedDiet | Lifestyle | Ionizing Radiation ExposureUnited States
-
University of California, San FranciscoAlbert Einstein Healthcare Network; National Cancer Institute (NCI); University... and other collaboratorsCompletedQuality Improvement | Ionizing Radiation Exposure
-
Instituto de Cardiologia do Rio Grande do SulCompletedRadiation Injury | Exposure to Ionizing Radiation | Occupational Exposure to RadiationBrazil
-
The Federal Office for Radiation Protection, GermanySeibersdorf Labor GmbHCompleted
-
Chulalongkorn UniversityCompletedExposure to Ionizing RadiationThailand
-
NYU Langone HealthRecruitingRadiation ExposureUnited States
-
Central Hospital, Nancy, FranceNot yet recruitingExposure, RadiationFrance
-
Eric A. HoffmanCompleted
Clinical Trials on Cell therapy
-
Royan InstituteTehran University of Medical Sciences; Shahid Beheshti University of Medical...UnknownCovid-19Iran, Islamic Republic of
-
Nantes University HospitalUnknown
-
General Hospital of Chinese Armed Police ForcesUnknownHereditary Cerebellar Ataxia.China
-
Columbia UniversityOssium Health, Inc.RecruitingIntestinal TransplantationUnited States
-
Anhui Provincial HospitalEnrolling by invitationCirrhosis, LiverChina
-
Lung InstituteCompletedInterstitial Lung Disease | COPDUnited States
-
Ministry of Health, BrazilCompletedCoronary Artery Disease | Angina Pectoris | Chronic Ischemic Heart DiseaseBrazil
-
National Heart, Lung, and Blood Institute (NHLBI)NIH Heart Center at Suburban HospitalTerminatedCoronary Artery Disease | Ischemic Heart Disease | Heart Disease | Coronary Artery Disease (CAD)United States
-
Royan InstituteCompletedLeg Length InequalityIran, Islamic Republic of
-
Chinese Academy of SciencesNational Natural Science Foundation of China; The First Affiliated Hospital...Active, not recruitingPrimary Ovarian InsufficiencyChina